tradingkey.logo

enVVeno Medical Corp

NVNO

4.950USD

+0.080+1.64%
Market hours ETQuotes delayed by 15 min
95.27MMarket Cap
LossP/E TTM

enVVeno Medical Corp

4.950

+0.080+1.64%
More Details of enVVeno Medical Corp Company
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
Company Info
Ticker SymbolNVNO
Company nameenVVeno Medical Corp
IPO dateMay 31, 2018
CEOMr. Robert A. Berman
Number of employees37
Security typeOrdinary Share
Fiscal year-endMay 31
Address70 Doppler
CityIRVINE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92618
Phone19492612900
Websitehttps://envveno.com/
Ticker SymbolNVNO
IPO dateMay 31, 2018
CEOMr. Robert A. Berman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Shareholders
Shareholders
Proportion
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Shareholder Types
Shareholders
Proportion
Hedge Fund
10.14%
Investment Advisor
6.99%
Investment Advisor/Hedge Fund
2.62%
Research Firm
1.20%
Individual Investor
0.92%
Venture Capital
0.17%
Private Equity
0.14%
Other
77.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
72
3.82M
21.80%
-3.16M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
2023Q1
54
2.76M
29.13%
-1.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kingdon Capital Management, L.L.C.
859.26K
4.9%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
600.91K
3.43%
+11.77K
+2.00%
Mar 31, 2025
Nantahala Capital Management, LLC
594.66K
3.39%
-2.26K
-0.38%
Mar 31, 2025
UBS O'Connor LLC
296.03K
1.69%
--
--
Mar 31, 2025
Westside Investment Management, LLC
259.05K
1.48%
+54.02K
+26.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
197.30K
1.13%
+15.56K
+8.56%
Mar 31, 2025
J.P. Morgan Securities LLC
194.21K
1.11%
-75.83K
-28.08%
Mar 31, 2025
Altium Capital Management LP
123.26K
0.7%
-186.74K
-60.24%
Mar 31, 2025
Duhay (Francis)
102.34K
0.58%
--
--
Feb 26, 2025
Dauntless Investment Group, LLC
70.85K
0.4%
+70.85K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Date
Type
Ratio
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
KeyAI